Nanoform and Celanese Corporation have announced plans to explore the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery.

The goal is to assess the utility of combining Nanoform’s nanoparticle platform technologies with Celanese’s VitalDose EVA copolymer delivery technology for drug-eluting implants, states Nanoform in a press release. The aims are to enable the development of next-generation drug delivery devices that support increased drug load and possess enhanced sustained release properties. Nanoform and Celanese intend to work on formulation development, leveraging each organization’s unique formulation expertise.

“We are delighted to announce the relationship with Celanese. One of Nanoform’s fundamental goals is to enable next-generation drug therapies using our nanoparticles. Given the inherent difficulty in loading a sufficient amount of drug into many medical devices, we see a tremendous opportunity in using our nanoparticles to overcome this fundamental challenge. The potential to leverage the combination of these two technologies to bring new therapies to patients is something we are very excited about,” says Edward Hæggström, CEO of Nanoform.

Photo: Nanoform